TNKASE (tenecteplase) / Boehringer Ingelheim, Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
MK02-2016-01, NCT04676659: Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events(TRACE)

Completed
2
240
RoW
TNK-tPA, rtPA
Beijing Tiantan Hospital, Guangzhou Recomgen Biotech Co., Ltd., The First Hospital Of Qiqihar, Hebei Medical University Third Hospital, Yantai Yuhuangding Hospital, Fudan University, First Affiliated Hospital of Jinan University, First Hospital of Jilin University, Huashan Hospital, West China Hospital, Inner Mongolia Baogang Hospital, Linyi People's Hospital, The First Affiliated Hospital of Zhengzhou University, Baotou Central Hospital
Acute Ischemic Stroke
05/20
07/20
NCT04505592: Tenecteplase in Patients With COVID-19

Completed
2
13
US
Tenecteplase, Placebo
Hooman Poor, Genentech, Inc.
COVID-19, Respiratory Failure, ARDS
03/22
03/22
ALLY, NCT05172934: Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy Pilot Trial

Completed
2
20
US
intra-arterial tenecteplase
ProMedica Health System, Genentech, Inc.
Ischemic Stroke
09/23
11/23

Download Options